Opendata, web and dolomites

HifLICs SIGNED

Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HifLICs project word cloud

Explore the words cloud of the HifLICs project. It provides you a very rough idea of what is the project "HifLICs" about.

transcriptional    molecular    practical    diseases    cellular    benefit    scientific    heterogeneous    metabolically    regulated    group    tumor    inactive    therapies    mediates    extend    suggested    aml    disease    patient    investigator    treatment    types    vs    transcription    hypoxia    dormant    hematopoietic    stage    quite    broad    initiating    criteria    cells    suppressor    driving    diagnosis    techniques    hifs    localization    relapse    constitutes    human    clinical    caused    supporting    classified    subgroup    acquired    complementary    resistant    therapeutic    resistance    samples    inducible    tumors    alterations    progenitor    empowering    bone    oncogenic    genetic    solid    pathogenesis    technologies    independent    single    thought    cytogenetic    susceptible    date    survive    genotoxic    acute    cytotoxic    myeloid    cell    me    dormancy    controversial    family    leukemia    heterogeneity    barrier    therapy    candidate    drugs    niche    hypoxic    hif    genes    pointing    near    regulators    marrow    lics    action    lic    chemotherapy    substantial   

Project "HifLICs" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS 

Organization address
address: CARRER MUNTANER 383 3/2
city: BARCELONA
postcode: 8021
website: www.carrerasresearch.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Acute myeloid leukemia (AML) is a heterogeneous group of diseases caused by acquired cytogenetic and molecular alterations in hematopoietic progenitor cells. There is a substantial need to develop new therapeutic approaches to AML; however, the genetic heterogeneity of AML constitutes a barrier for the development of targeted therapies. Leukemia relapse after treatment is most often caused by a subgroup of cells commonly referred to as leukemia initiating cells (LICs), which are resistant to chemotherapy. It is thought that this resistance is the result of several properties unique to LICs, including their dormant and metabolically inactive state, making them less susceptible to genotoxic drugs. The localization of the LICs in the hypoxic bone marrow niche has been proposed as a driving factor for dormancy. The HIF (hypoxia-inducible factor) family of transcription factors mediates cellular adaptation to hypoxia. While the role of HIFs in the pathogenesis of solid tumors is quite well established, they have only recently been suggested as key regulators of LICs in specific types of leukemia. Yet, results to date are highly controversial, with some studies supporting an oncogenic activity for HIFs and others pointing to a tumor suppressor role.

We propose a broad transcriptional study of human AML classified by cytogenetic criteria and disease stage (diagnosis vs relapse). We will focus on HIF-regulated target genes in the LIC subgroup and evaluate LIC heterogeneity using state-of-the-art single-cell technologies. Our results should extend our understanding of the ability of LICs to survive cytotoxic therapy and help to identify candidate targets for clinical application.

The use of AML patient samples and single-cell techniques included in this proposal will increase my scientific knowledge and practical experience. I will also benefit from the complementary planned activities of the action, empowering me to become an independent investigator in the near future.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIFLICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HIFLICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GRAHAM (2018)

Concepts of Graph Theory Applied to the Human Microbiome

Read More  

deCrYPtion (2019)

Decrypting Mycobacterium cytochrome P450 (CYP) physiological functions by testing hypotheses emitted form large-scale comparative genomics analysis

Read More  

NeuroTick (2019)

The neuroscience of tickling: cerebellar mechanisms and sensory prediction

Read More